Clinical guidelines from the International Working Group–Myeloproliferative Neoplasms Research and Treatment and European LeukemiaNet state that appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin indicates progressive disease.
Progressive disease assignment for splenomegaly requires confirmation by CT or MRI showing a ≥ 25% increase in spleen volume from pretreatment baseline.
Learn more about how imaging studies may be used in the workup of a patient with PMF.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emmanuel C. Besa. Fast Five Quiz: Prognosis of Primary Myelofibrosis - Medscape - Jul 16, 2020.